Percentage of Participants With Composite Efficacy Failure at 12 Months 12 Months [clinicaltrials_resource:70106fcc26b32b5be21898023297ef2d]
Composite efficacy failure was defined as Biopsy Proven Acute Rejection(BPAR) of International Society for Heart and Lung Transplantation(ISHLT) grade ≥3A, Acute Rejection associated with Hemodynamic Compromise, Graft loss/Retransplant, Death or Loss to follow-up.
Identification of acute rejection was based on the local pathologist's evaluation of endomyocardial biopsy slides.
Hemodynamic compromise was present if 1 or more of the following were met: Ejection fraction ≤30% or 25% lower than Baseline or Fractional shortening ≤20% or 25% lower than Baseline and/or use of inotropic treatment.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Percentage of Participants With Composite Efficacy Failure at 12 Months 12 Months [clinicaltrials_resource:70106fcc26b32b5be21898023297ef2d]
Composite efficacy failure was defined as Biopsy Proven Acute Rejection(BPAR) of International Society for Heart and Lung Transplantation(ISHLT) grade ≥3A, Acute Rejection associated with Hemodynamic Compromise, Graft loss/Retransplant, Death or Loss to follow-up.
Identification of acute rejection was based on the local pathologist's evaluation of endomyocardial biopsy slides.
Hemodynamic compromise was present if 1 or more of the following were met: Ejection fraction ≤30% or 25% lower than Baseline or Fractional shortening ≤20% or 25% lower than Baseline and/or use of inotropic treatment.
Bio2RDF identifier
70106fcc26b32b5be21898023297ef2d
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:70106fcc26b32b5be21898023297ef2d
measure [clinicaltrials_vocabulary:measure]
Percentage of Participants With Composite Efficacy Failure at 12 Months
time frame [clinicaltrials_vocabulary:time-frame]
description
Composite efficacy failure was ...... or use of inotropic treatment.
identifier
clinicaltrials_resource:70106fcc26b32b5be21898023297ef2d
title
Percentage of Participants With Composite Efficacy Failure at 12 Months 12 Months
@en
type
label
Percentage of Participants Wit ...... 06fcc26b32b5be21898023297ef2d]
@en